Navigation Links
Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China's Guidebook for Pharmaceutical Patent Protection

http://www.reportlinker.com/p0512262/-China's-Guidebook-for-Pharmaceutical-Patent-Protection.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Description

China is expected to become the fifth largest drug market in the world by 2010 with a growth rate of 20-25 percent per annum in next three years. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door to a lucrative drug market for overseas pharmaceutical companies, which attracts more and more overseas pharmaceutical manufacturers and producers to enter such drug market and seize a larger part of such drug market. However, the Chinese social environment for the protection of intellectual property right is complex. The locally produced generics and copy products dominate the Chinese drug market. It is estimated that about 97 percent of the drugs produced by local companies are generics or counterfeits.

Facing such complex social environment and market, most overseas and multinational pharmaceutical companies fear that their imported drugs and pharmaceuticals produced in China will be imitated or copied, in turn, their intellectual property will be infringed and benefit will be violated. What reason incurred such fear of overseas and multinational pharmaceutical companies? Why did Eli Lilly & Company fail in its litigation of patent infringement dispute case in China? Why can Pfizer win in an administrative proceeding against the Patent Reexamination Board of the China State Intellectual Property Office (SIPO) for its Viagra patent? Lack of knowledge of the Chinese intellectual property right system and legislation institution, the cultural difference between China and Western countries as well as the language barriers incurred such result.

China's Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual property in China. This guidebook, targeting overseas and multinational pharmaceutical companies and combining case studies of patent infringement dispute in China from them, will provide a comprehensive and thorough knowledge of the Chinese patent system and legislation institution to guide overseas and multinational pharmaceutical companies step by step to achieve a successful patent protection for their intellectual property in China, which is beginning from the organization structure and the responsibility of Chinese patent authorities, the application for patent, the examination and approval of application for patent, the protection of patent right, to design for compositions of optimized patent protection strategies. Its audiences are the executives from overseas and multinational pharmaceutical companies who have the preliminary knowledge of patent. It is also a textbook for the readers studying in the patent protection for intellectual property rights relating to pharmaceuticals. After having skimmed through this guidebook, audiences and readers can not only be clearly aware of the Chinese patent system and legislation institution, but also design an optimized patent protection strategy for themselves to acquire an adequate protection for their patent right in China.

Guidebook Highlights

China's Guidebook for Pharmaceutical Patent Protection provides a comprehensive and thorough knowledge of the Chinese patent system relating to pharmaceuticals, the detailed administrative, civil and criminal judicial pathways for protections of patent right, and the design for composition of optimized protection strategies.

- The organization structure of patent authorities and judicial system;

- A comprehensive and thorough knowledge of the Chinese patent system and the relevant laws and administrative regulations relating to pharmaceuticals;

- The patentable subject matter relating to pharmaceuticals in China;

- Administrative protection for patent right;

- Civil judicial procedures and remedies for patent right;

- Criminal punitions for infringement of patent right;

- Design for compositions of optimized protection strategies;

Table of Contents

Executive Summary 4

Preface 6

Chapter 1. Introduction 9

Chapter 2 . Organization Structure of Patent Authorities and Judicial

System 12

2.1. Organization Structure of Patent Authorities 12

2.2. Organization Structure of Judicial System 14

2.3. Responsibilities of the State Intellectual Property Office (SIPO) 15

2.3.1. Responsibilities of the Patent Office 15

2.3.2. Responsibilities of the Patent Reexamination Board 16

Chapter 3. The Objects of Patent Right 17

3.1. The Objects of Patent Right 17

3.2. The Non-Patentable Subject Matter 18

Chapter 4. The Patentable Subject Matter Relating to Pharmaceuticals 19

4.1. The Patentable Subject Matters for Invention 19

4.2. The Patentable Subject Matters for Utility Model 22

4.3. The Patentable Subject Matters for Design 22

Chapter 5. Application for Patent 23

5.1. The Right of Patent Application 23

5.2. The Applicant for Patent 24

5.3.1. The Date of Filing 25

5.3.2. The Priority Date 25

5.4. Application for Patent 27

5.4.1. Application for a Patent for Invention or Utility Model 28

5.4.2. Application for a Patent for Design 33

Chapter 6. Examination and Approval of Application for Patent 34

6.1. Examination and Approval of Application for Patent for Invention 35

6.2. Examination and Approval of Application for Patent for Utility Model and Design 42

6.3. Examination and Approval Procedure of Application for Patent for Invention 48

6.4. Examination and Approval Procedure of Application for Patent for Utility Model or

Design 50

Chapter 7. Reexamination of Patent Application and Invalidation of Patent Right 51

7.1. Reexamination of Patent Application 51

7.2. Reexamination of Invalidation of Patent Right 53

Chapter 8. Legitimate Rights and Liabilities of Patentee 56

8.1. Legitimate Rights and Interests of Patentee 56

8.2. Legitimate Liabilities of Patentee 58

Chapter 9. Limitation of Patent Right 58

9.1. Exceptions to Patent Right Conferred 59

9.2. Compulsory License for Exploitation of Patent 60

Chapter 10. Protection of Patent Right 62

10.1. Duration and Scope of Patent Right Protection 62

10.2. Infringement of Patent Right and Legal Liability of Infringer 62

10.2.1. Infringement of Patent Right 63

10.2.2. Legal Liability of Infringer 64

10.3. Administrative Protection for Patent Right 65

10.3.1. Administrative Protection of the Patent Authorities 65

10.3.2. Administrative Protection of the Customs 67

10.4. Administrative Judicial Procedures for Protection of Patent Right 73

10.5. Civil Judicial Procedures and Remedies for Patent Right 74

10.5.1. Scope of Civil Patent Disputes 74

10.5.2. Jurisdiction 75

10.5.3. The Time Limit of Litigation 76

10.5.4. Application for Pre-trial Cessation of Infringement and Property Preservation 76

10.5.5. Litigation 79

10.5.6. Remedies and Compensations 81

10.6. Criminal Punitions for Infringement of Patent Right 83

Chapter 11. Compositions of Optimized Protection Strategies 83

11.1. Optimized Patent Protection Strategies based on the Kind of Patent Right 84

11.1.1. Review of Some Essentials of Knowledge 84

11.1.2. Compositions of Optimized Patent Protection Strategies based on the

Kind of Patent Right 87

11.1.3. Case Studies 91

11. 2. Optimized Protection Strategies beyond Patent Right 99

11.2.1. Case Study: Pfizer's Viagra Patent and Trademark Dispute in China 100

11.2.2. Essential Knowledge of Registered Trademark in China 107

11.2.3. Optimized Protection Strategies beyond Patent Right 113

Chapter 12. Appendices 114

12.1. Case 1: A Patent Infringement Dispute of Eli Lilly (Eli Lilly and Company)

v. Jiangsu Hansoh Pharmaceutical Corporation & Shanghai Institute of

Pharmaceutical Industry in China 114

12.2. Case 2:: A Patent Infringement Dispute of Abbott Laboratories v. Andrx

Pharmaceuticals, INC. 130

12.3. List of the People's Courts Accepting First Instance Administrative and

Civil Litigations for Patent Case 150

12.4. Patent Registration and Patent Gazette in China 153

12.4.1. Patent Registration in China 153

12.4.2. Patent Gazette in China 153

12.5. References 155

12.6. Resources 157

12.7. Author's Biography 158

12.8. Company's Description 159

To order this report:

Drug and Medication Industry: China's Guidebook for Pharmaceutical Patent Protection

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Greece Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2017
2. Reportlinker Adds Global Top 10 Pharmaceutical Companies: Industry, Financial and SWOT Analysis
3. Reportlinker Adds the Future of In Vitro and In Vivo Diagnostic Integration
4. Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018
5. Reportlinker Adds Epidemiology: Major Abdominal Surgery - A key risk factor for deep vein thrombosis and pulmonary embolism
6. Reportlinker Adds The Antibacterials Market Outlook to 2016
7. Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
8. Reportlinker Adds The Drug-Eluting Stent Market Outlook to 2016
9. Reportlinker Adds The Infusion Pump Market Outlook to 2016
10. Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook
11. Reportlinker Adds Advances in Drug-Diagnostic Co-Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ZIONA SCIENCE PARK , Israel ... company Kadimastem (TASE: KDST) announced today the signing of a memorandum ... between the companies. The synergy between the companies will assist in ... as a worldwide leader in innovative treatment for severe diseases in ... ...
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
(Date:12/7/2016)... The global  blood screening ... USD 3.9 billion by 2024, based on a ... growth of the market is attributed to the ... by the market players. Demand for blood screening ... rising awareness about transfusion-transmitted diseases, and technological developments ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco ... services to residents in the Sacramento/Folsom region, is initiating a charity event to ... The Another Choice Another Chance treatment center in Sacramento works to provide area ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... Chicago, IL (PRWEB) , ... December 07, 2016 , ... ... giving back this holiday season by donating a portion of proceeds to two local ... North Chicago Animal Control & Friends is a team of authorized and ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
Breaking Medicine News(10 mins):